市場調查報告書
商品編碼
1068692

學名藥的全球市場:各產品類型,各給藥途徑,各應用領域,各流通管道,各地區,趨勢分析,競爭市場佔有率,預測(2018年∼2028年)

Global Generic Drugs Market; By Product Type ; By Route of Administration ; By Application ; By Distribution Channel ; By Region ; Trend Analysis, Competitive Market Share & Forecast, 2018-2028

出版日期: | 出版商: Blueweave Consulting & Research Private Limited | 英文 254 Pages | 商品交期: 請詢問到貨日

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球學名藥的市場規模,預計從2021年的4,050億美元到2028年達到7,450億美元,在預測期間內預計以11.1%的年複合成長率成長。

由於全球健康問題的擴大,對研究開發的投資增加,貧困國和中所利益國對低成本醫藥品的需求劇增,市場成長。再加上醫療費增加和活躍世代的健康意識高漲,也牽引著全球學名藥市場。

本報告提供全球學名藥市場的相關調查,市場概要,市場分析,企業簡介等全面性資訊。

目錄

第1章 調查組成架構

第2章 調查手法

第3章 摘要整理

第4章 全球學名藥市場-產業考察

  • 產業的價值鏈/供應鏈
  • DROC分析
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 課題
  • 最近的開發/技術性形勢
  • 法律規範
  • 波特的五力分析

第5章 全球學名藥市場概要(2018年∼2028年)

  • 市場規模與預測
    • 各金額(10億美元)
  • 市場佔有率與預測
    • 各產品類型
      • 簡便非專利
      • 超級非專利藥品
      • 生物相似藥
    • 各給藥途徑
      • 口服
      • 局部
      • 注射
      • 其他
    • 各應用領域
      • 心臟血管產品
      • 抗感染藥
      • 抗關節炎藥
      • 中樞神經系統藥
      • 抗癌劑
      • 呼吸系統產品
      • 其他
    • 各流通管道
      • 醫院/診所
      • 零售藥局
      • 其他
    • 各地區
      • 北美
      • 歐洲
      • 亞太地區
      • 南美
      • 中東、非洲

第6章 北美的學名藥市場概要(2018年∼2028年)

  • 市場規模與預測
    • 各金額(10億美元)
  • 市場佔有率與預測
    • 各產品類型
    • 各給藥途徑
    • 各應用領域
    • 各流通管道
    • 各國
      • 美國
      • 加拿大

第7章 歐洲的學名藥市場概要(2018年∼2028年)

  • 市場規模與預測
    • 各金額(10億美元)
  • 市場佔有率與預測
    • 各產品類型
    • 各給藥途徑
    • 各應用領域
    • 各流通管道
    • 各國
      • 德國
      • 法國
      • 義大利
      • 西班牙
      • 英國
      • 荷蘭
      • 其他的歐洲

第8章 亞太地區的學名藥市場概要(2018年∼2028年)

  • 市場規模與預測
    • 各金額(10億美元)
  • 市場佔有率與預測
    • 各產品類型
    • 各給藥途徑
    • 各應用領域
    • 各流通管道
    • 各國
      • 中國
      • 印度
      • 日本
      • 韓國
      • 其他的亞太地區

第9章 南美的學名藥市場概要(2018年∼2028年)

  • 市場規模與預測
    • 各金額(10億美元)
  • 市場佔有率與預測
    • 各產品類型
    • 各給藥途徑
    • 各應用領域
    • 各流通管道
    • 各國
      • 阿根廷
      • 巴西
      • 墨西哥
      • 其他的南美

第10章 中東及非洲的學名藥市場概要(2018年∼2028年)

  • 市場規模與預測
    • 各金額(10億美元)
  • 市場佔有率與預測
    • 各產品類型
    • 各給藥途徑
    • 各應用領域
    • 各流通管道
    • 各國
      • 沙烏地阿拉伯
      • 南非
      • 阿拉伯聯合大公國
      • 其他的中東

第11章 競爭情形

    • 主要企業提供的清單
    • 市場佔有率分析(2021年)
    • 競爭基準:各行動參數
    • 主要的開發與成長策略
      • 合併和收購

第12章 COVID-19影響

第13章 企業簡介概要(企業概要,財務矩陣,主要的產品類型的形勢,主要的人員,主要的其他競爭公司,聯絡原住所,及策略性展望)*

  • Teva Pharmaceutical Industries
  • Fresenius Kabi
  • Sandoz, a Novartis Divison
  • Mylan N.V.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Limited
  • Mallinckrodt Pharmaceuticals
  • Stada Arzneimittel AG
  • Aurobindo Pharma Limited
  • Endo International plc.
  • Aspen Pharmacare Holdings Limited
  • Dr. Reddy's Laboratories
  • Cipla Limited
  • Hikma Pharmaceuticals plc.
  • Piramal Pharma Solutions
  • LUPIN Limited
  • Sawai Pharmaceutical Co. Ltd.
  • Amneal Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Torrent Pharmaceuticals Ltd.
  • 其他

第14章 主要策略性推薦事項

*非表列公司的財務訊息將視情況提供。

**市場區隔及企業,根據詳細補充資訊有變更的可能性。

目錄
Product Code: BWC22044

Generic Drugs Market to Reach USD 745 Billion by 2028

The global generic drugs market is growing with the increasing prevalence of health issues, increasing investment in R&D, growth of biopharma industry, and growing demand for low-cost medicines from poor and middle-income countries…

A study, recently conducted by the strategic consulting and market research firm BlueWeave Consulting, revealed that the global generic drugs was valued at USD 405 billion in 2021and is forecast to cross USD 745 billion by 2028. The global generic drugs market is growing due to the increasing prevalence of health issues around the globe, increasing investment in R&D, and surging demand for low-cost medicines from poor and middle-income countries. Additionally, growing healthcare expenditures and increasing health awareness among the current generation are driving the global generic drugs market.

Rise in chronic and non-chronic diseases is propelling the growth of the global generic drugs market

Globally, chronic and non-chronic diseases are growing at an alarming rate and generic drugs are helping to control the number of deaths due to these health issues. As per the WHO's estimation, 42% of children less than five years of age and 40% of pregnant women worldwide are anemic. According to the International Agency for Research on Cancer, there were almost 19.3 million new cases of cancer in 2020 with around 10 million cancer-related deaths. The agency further estimated that the global cancer cases would increase by 28.4 million by 2040. Furthermore, according to the WHO, non-chronic diseases are responsible for around 70% of deaths around the world every year.

People are increasingly choosing generic drugs over branded medications due to the cost-effectiveness of generic drugs that have the same potency and effectiveness. This shift in trend has fueled the demand for generic drugs in the market and contributed to the growth of the market during the historic period. In addition, generic drugs are seen as a suitable alternative to branded drugs due to easier manufacturing and easier regulations. This factor, coupled with the increasing demand for generic drugs, is expected to drive the growth of the global generic drugs market during the forecast period.

Injectable Segment Dominates the Global Generic Drugs Market

Based on the route of administration, the global generic drugs market is grouped into topical, oral, injectable, and others. During the forecast period, the injectable segment is expected to grow owing to the growing number of injectable drugs in the market. Additionally, the emergence of the biopharma industry and the growing number of generic vaccines in the market are expected to propel the growth of the injectable segment during the forecast period.

Request for Sample Report @ https://www.blueweaveconsulting.com/report/generic-drugs-market/report-sample

Impact of COVID-19

COVID-19 severely affected all industries around the world; however, only a few industries were affected as severely as the pharmaceutical industry. Increasing coronavirus cases around the world led to a surge in demand for generic and branded drugs. Moreover, during the pandemic, people turned to generic drugs because of the high cost of branded drugs. Furthermore, the FDA provided USD 20 million for science and research programs of generic drugs in the United States. Due to the emergence of the Omicron variant of the Coronavirus and the upcoming launch of a generic version of the COVID-19 vaccine, the demand for generic drugs is predicted to increase significantly over the next few years.

Global Generic Drugs Market: Regional insights

Based on regions, the global photovoltaic rapid shutdown device market is classified into North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The North American market dominated in 2021 owing to the high number of generic AIDS and cancer drugs on the market. The high cost of healthcare in the region has further encouraged people to go for generic drugs rather than branded drugs due to the cost-effective nature of generic drugs. Additionally, the growing number of health issues and the presence of global leaders have supported the growth of the global generic drugs market in the region.

The leading players in the global generic drugs market are Teva Pharmaceutical Industries, Fresenius Kabi, and Sandoz, a Novartis Divison. Other major players operating in the market are Mylan N.V., Sanofi S.A., Sun Pharmaceutical Industries Limited, Mallinckrodt Pharmaceuticals, Stada Arzneimittel AG, Aurobindo Pharma Limited, Endo International plc., Aspen Pharmacare Holdings Limited, Dr. Reddy's Laboratories, Cipla Limited, Hikma Pharmaceuticals plc., Piramal Pharma Solutions, LUPIN Limited, Sawai Pharmaceutical Co. Ltd., Amneal Pharmaceuticals, Inc., Glenmark Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd., and other prominent players.

The global generic drugs market is fragmented market with a number of major players operating in the market. There is fierce competition between the new companies and the established companies in the market for market share. Collaboration, merger & acquisitions, partnerships, and the launch of new projects are some of the strategies used by players in the generic drugs market to gain an advantage over their competitors.

Recent Developments

In January 2022, Alembic Pharmaceuticals Limited received FDA approval for its Abbreviated New Drug Application (ANDA) for Doxycycline Hyclate Delayed-Release Tablets USP, 75 mg, 100 mg, 150 mg, and 200 mg. The company further announced that the approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Doryx Tablets, 75 mg, 100 mg, 150 mg, and 200 mg, of Mayne Pharma International Pty. Ltd. (Mayne).

In January 2022, the Philippines FDA approved world's first generic version of Pfizer's anti-coronavirus pill, Paxlovid. The approval from the Philippines FDA has come just days after it received emergency use authorization from the United States FDA. The generic version of Paxlovid has been developed by Beximco Pharmaceutical, a leading generic drug manufacturer from Bangladesh.

Don't miss the business opportunity of the global generic drugs market. Consult our analyst, gain crucial insights and facilitate your business growth.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of global generic drugs market size & forecast. The report promises to provide recent technology trends of global generic drugs market and industry insights which help decision-makers to make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Type Overview
  • 1.3. Market Segmentation

2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary and Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary and Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents
    • 2.3.1. Secondary Research
    • 2.3.2. Primary Research
  • 2.4. Breakdown of Primary Research Respondents, By Industry Participants
  • 2.5. Key Questionnaire asked during Primary Interviews
  • 2.6. Key Primary Responses
  • 2.7. Market Size Estimation
  • 2.8. Assumption for the Study
  • 2.9. Market Breakdown & Data Triangulation

3. Executive Summary

4. Global Generic Drugs Market - Industry Insights

  • 4.1. Industry Value Chain/Supply Chain
  • 4.2. DROC Analysis
    • 4.2.1. Growth Drivers
    • 4.2.2. Restraints
    • 4.2.3. Opportunity
    • 4.2.4. Challenges
  • 4.3. Recent Developments / Technical Landscape
  • 4.4. Regulatory Framework
  • 4.5. Porter's Five Forces Analysis

5. Global Generic Drugs Market Overview, 2018-2028

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type
      • 5.2.1.1. Simple Generics
      • 5.2.1.2. Super Generics
      • 5.2.1.3. Biosimilars
    • 5.2.2. By Route of Administration
      • 5.2.2.1. Oral
      • 5.2.2.2. Topical
      • 5.2.2.3. Injectable
      • 5.2.2.4. Others
    • 5.2.3. By Application
      • 5.2.3.1. Cardiovascular Products
      • 5.2.3.2. Anti-infective Drugs
      • 5.2.3.3. Anti-arthritis Drugs
      • 5.2.3.4. Central Nervous System Drugs
      • 5.2.3.5. Anti-Cancer Drugs
      • 5.2.3.6. Respiratory Products
      • 5.2.3.7. Other
    • 5.2.4. By Distribution Channel
      • 5.2.4.1. Hospitals/Clinics
      • 5.2.4.2. Retail Pharmacies
      • 5.2.4.3. Other
    • 5.2.5. Region
      • 5.2.5.1. North America
      • 5.2.5.2. Europe
      • 5.2.5.3. Asia-Pacific
      • 5.2.5.4. Latin America
      • 5.2.5.5. Middle East & Africa

6. North America Generic Drugs Market Overview, 2018-2028

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By Route of Administration
    • 6.2.3. By Application
    • 6.2.4. By Distribution Channel
    • 6.2.5. By Country
      • 6.2.5.1. United States
      • 6.2.5.2. Canada

7. Europe Generic Drugs Market Overview, 2018-2028

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By Route of Administration
    • 7.2.3. By Application
    • 7.2.4. By Distribution Channel
    • 7.2.5. By Country
      • 7.2.5.1. Germany
      • 7.2.5.2. France
      • 7.2.5.3. Italy
      • 7.2.5.4. Spain
      • 7.2.5.5. UK
      • 7.2.5.6. Netherlands
      • 7.2.5.7. Rest of Europe

8. Asia-Pacific Generic Drugs Market Overview, 2018-2028

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Application
    • 8.2.4. By Distribution Channel
    • 8.2.5. By Country
      • 8.2.5.1. China
      • 8.2.5.2. India
      • 8.2.5.3. Japan
      • 8.2.5.4. South Korea
      • 8.2.5.5. Rest of Asia-Pacific

9. Latin America Generic Drugs Market Overview, 2018-2028

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By Route of Administration
    • 9.2.3. By Application
    • 9.2.4. By Distribution Channel
    • 9.2.5. By Country
      • 9.2.5.1. Argentina
      • 9.2.5.2. Brazil
      • 9.2.5.3. Mexico
      • 9.2.5.4. Rest of Latin America

10. Middle East & Africa Generic Drugs Market Overview, 2018-2028

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value (USD Billion)
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By Route of Administration
    • 10.2.3. By Application
    • 10.2.4. By Distribution Channel
    • 10.2.5. By Country
      • 10.2.5.1. Saudi Arabia
      • 10.2.5.2. South Africa
      • 10.2.5.3. UAE
      • 10.2.5.4. Rest of Middle East & Africa

11. Competitive Landscape

    • 11.1.1. List of Key Producers and Their Offerings
    • 11.1.2. Market Share / Ranking Analysis (2021)
    • 11.1.3. Competitive Benchmarking, By Operating Parameters
    • 11.1.4. Key Developments & Growth Strategies
      • 11.1.4.1. Mergers & Acquisitions

12. COVID-19 Impact

13. Company Profiles (Company Overview, Financial Matrix, Key Product Type landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *

  • 13.1. Teva Pharmaceutical Industries
  • 13.2. Fresenius Kabi
  • 13.3. Sandoz, a Novartis Divison
  • 13.4. Mylan N.V.
  • 13.5. Sanofi S.A.
  • 13.6. Sun Pharmaceutical Industries Limited
  • 13.7. Mallinckrodt Pharmaceuticals
  • 13.8. Stada Arzneimittel AG
  • 13.9. Aurobindo Pharma Limited
  • 13.10. Endo International plc.
  • 13.11. Aspen Pharmacare Holdings Limited
  • 13.12. Dr. Reddy's Laboratories
  • 13.13. Cipla Limited
  • 13.14. Hikma Pharmaceuticals plc.
  • 13.15. Piramal Pharma Solutions
  • 13.16. LUPIN Limited
  • 13.17. Sawai Pharmaceutical Co. Ltd.
  • 13.18. Amneal Pharmaceuticals, Inc.
  • 13.19. Glenmark Pharmaceuticals Limited
  • 13.20. Torrent Pharmaceuticals Ltd.
  • 13.21. Other Prominent Players

14. Key Strategic Recommendations

* Financial information of non-listed Companies will be provided as per availability

**The segmentation and the companies are subjected to modifications based on in-depth study during the final deliverable.

List of Figures

  • Fig 1: Global Generic Drugs Segmentation
  • Fig 2: Global Generic Drugs Market Value Chain Analysis
  • Fig 3: Global Generic Drugs Market Size, By Value (USD Billion), 2018-2028
  • Fig 4: Global Generic Drugs Market Share, By Product Type, By Value, 2018-2028
  • Fig 5: Global Generic Drugs Market Share, By Route of Administration, By Value, 2018-2028
  • Fig 6: Global Generic Drugs Market Share, By Application, By Value, 2018-2028
  • Fig 7: Global Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028
  • Fig 8: Global Generic Drugs Market Share, By Region, By Value, 2018-2028
  • Fig 9: North America Generic Drugs Market Size, By Value (USD Billion), 2018-2028
  • Fig 10: North America Generic Drugs Market Share, By Product Type, By Value, 2018-2028
  • Fig 11: North America Generic Drugs Market Share, By Route of Administration, By Value, 2018-2028
  • Fig 12: North America Generic Drugs Market Share, By Application, By Value, 2018-2028
  • Fig 13: North America Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028
  • Fig 14: North America Generic Drugs Market Share, By Country By Value, 2018-2028
  • Fig 15: Europe Generic Drugs Market Size, By Value (USD Billion), 2018-2028
  • Fig 16: Europe Generic Drugs Market Share, By Product Type, By Value, 2018-2028
  • Fig 17: Europe Generic Drugs Market Share, By Route of Administration, By Value, 2018-2028
  • Fig 18: Europe Generic Drugs Market Share, By Application, By Value, 2018-2028
  • Fig 19: Europe Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028
  • Fig 20: Europe Generic Drugs Market Share, By Country By Value, 2018-2028
  • Fig 21: Asia-Pacific Generic Drugs Market Size, By Value (USD Billion), 2018-2028
  • Fig 22: Asia-Pacific Generic Drugs Market Share, By Product Type, By Value, 2018-2028
  • Fig 23: Asia-Pacific Generic Drugs Market Share, By Route of Administration, By Value, 2018-2028
  • Fig 24: Asia-Pacific Generic Drugs Market Share, By Application, By Value, 2018-2028
  • Fig 25: Asia-Pacific Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028
  • Fig 26: Asia-Pacific Generic Drugs Market Share, By Country By Value, 2018-2028
  • Fig 27: Latin America Generic Drugs Market Size, By Value (USD Billion), 2018-2028
  • Fig 28: Latin America Generic Drugs Market Share, By Product Type, By Value, 2018-2028
  • Fig 29: Latin America Generic Drugs Market Share, By Route of Administration, By Value, 2018-2028
  • Fig 30: Latin America Generic Drugs Market Share, By Application, By Value, 2018-2028
  • Fig 31: Latin America Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028
  • Fig 32: Latin America Generic Drugs Market Share, By Country By Value, 2018-2028
  • Fig 33: Middle East & Africa Generic Drugs Market Size, By Value (USD Billion), 2018-2028
  • Fig 34: Middle East & Africa Generic Drugs Market Share, By Product Type, By Value, 2018-2028
  • Fig 35: Middle East & Africa Generic Drugs Market Share, By Route of Administration, By Value, 2018-2028
  • Fig 36: Middle East & Africa Generic Drugs Market Share, By Application, By Value, 2018-2028
  • Fig 37: Middle East & Africa Generic Drugs Market Share, By Distribution Channel, By Value, 2018-2028
  • Fig 38: Middle East & Africa Generic Drugs Market Share, By Country By Value, 2018-2028
  • Fig 39: Company Share Analysis, 2021

List of Tables

  • Table 1: Global Generic Drugs Size, By Product Type, By Value, 2018-2028
  • Table 2: Global Generic Drugs Market Size, By Route of Administration, By Value, 2018-2028
  • Table 3: Global Generic Drugs Market Size, By Application, By Value, 2018-2028
  • Table 4: Global Generic Drugs Market Size, By Distribution Channel, By Value, 2018-2028
  • Table 5: Global Generic Drugs Market Size, By Region, By Value, 2018-2028
  • Table 6: North America Generic Drugs Size, By Product Type, By Value, 2018-2028
  • Table 7: North America Generic Drugs Market Size, By Route of Administration, By Value, 2018-2028
  • Table 8: North America Generic Drugs Market Size, By Application, By Value, 2018-2028
  • Table 9: North America Generic Drugs Market Size, By Distribution Channel, By Value, 2018-2028
  • Table 10: North America Generic Drugs Market Size, By Region, By Value, 2018-2028
  • Table 11: Europe Generic Drugs Size, By Product Type, By Value, 2018-2028
  • Table 12: Europe Generic Drugs Market Size, By Route of Administration, By Value, 2018-2028
  • Table 13: Europe Generic Drugs Market Size, By Application, By Value, 2018-2028
  • Table 14: Europe Generic Drugs Market Size, By Distribution Channel, By Value, 2018-2028
  • Table 15: Europe Generic Drugs Market Size, By Region, By Value, 2018-2028
  • Table 16: Asia-Pacific Generic Drugs Size, By Product Type, By Value, 2018-2028
  • Table 17: Asia-Pacific Generic Drugs Market Size, By Route of Administration, By Value, 2018-2028
  • Table 18: Asia-Pacific Generic Drugs Market Size, By Application, By Value, 2018-2028
  • Table 19: Asia-Pacific Generic Drugs Market Size, By Distribution Channel, By Value, 2018-2028
  • Table 20: Asia-Pacific Generic Drugs Market Size, By Region, By Value, 2018-2028
  • Table 21: Latin America Generic Drugs Size, By Product Type, By Value, 2018-2028
  • Table 22: Latin America Generic Drugs Market Size, By Route of Administration, By Value, 2018-2028
  • Table 23: Latin America Generic Drugs Market Size, By Application, By Value, 2018-2028
  • Table 24: Latin America Generic Drugs Market Size, By Distribution Channel, By Value, 2018-2028
  • Table 25: Latin America Generic Drugs Market Size, By Region, By Value, 2018-2028
  • Table 26: Middle East & Africa Generic Drugs Size, By Product Type, By Value, 2018-2028
  • Table 27: Middle East & Africa Generic Drugs Market Size, By Route of Administration, By Value, 2018-2028
  • Table 28: Middle East & Africa Generic Drugs Market Size, By Application, By Value, 2018-2028
  • Table 29: Middle East & Africa Generic Drugs Market Size, By Distribution Channel, By Value, 2018-2028
  • Table 30: Middle East & Africa Generic Drugs Market Size, By Region, By Value, 2018-2028
  • Table 31: Teva Pharmaceutical Industries Business Overview
  • Table 32: Teva Pharmaceutical Industries Financial Analysis
  • Table 33: Fresenius Kabi Business Overview
  • Table 34: Fresenius Kabi Financial Overview
  • Table 35: Sandoz, A Novartis division Business Overview
  • Table 36: Sandoz, A Novartis division Financial Overview
  • Table 37: Mylan N.V., Business Overview
  • Table 38: Mylan N.V., Financial Overview
  • Table 39: Sanofi S.A., Business Overview
  • Table 40: Sanofi S.A., Financial Overview
  • Table 41: Sun Pharmaceutical Industries Limited Business Overview
  • Table 42: Sun Pharmaceutical Industries Limited Financial Analysis
  • Table 43: Mallinckrodt Pharmaceuticals Business Overview
  • Table 44: Mallinckrodt Pharmaceuticals Financial Analysis
  • Table 45: Stada Arzneimittel AG Business Overview
  • Table 46: Stada Arzneimittel AG Financial Analysis
  • Table 47: Aurobindo Pharma Limited Business Overview
  • Table 48: Aurobindo Pharma Limited Financial Overview
  • Table 49: Endo International plc., Business Overview
  • Table 50: Endo International plc., Financial Overview
  • Table 51: Aspen Pharmacare Holdings Limited Business Overview
  • Table 52: Aspen Pharmacare Holdings Limited Financial Overview
  • Table 53: Dr. Reddy's Laboratories Business Overview
  • Table 54: Dr. Reddy's Laboratories Financial Analysis
  • Table 55: Cipla Limited Business Overview
  • Table 56: Cipla Limited Financial Overview
  • Table 57: Hikma Pharmaceuticals plc., Business Overview
  • Table 58: Hikma Pharmaceuticals plc., Financial Overview
  • Table 59: Primal Pharma Solutions Business Overview
  • Table 60: Primal Pharma Solutions Financial Overview
  • Table 61: Lupin Limited Business Overview
  • Table 62: Lupin Limited Financial Overview
  • Table 63: Sawai Pharmaceutical Co. Ltd., Business Overview
  • Table 64: Sawai Pharmaceutical Co. Ltd., Financial Overview
  • Table 65: Amneal Pharmaceuticals, Inc., Business Overview
  • Table 66: Amneal Pharmaceuticals, Inc. Financial Overview
  • Table 67: Glenmark Pharmaceuticals Limited Business Overview
  • Table 68: Glenmark Pharmaceuticals Limited Financial Overview
  • Table 69: Torrent Pharmaceuticals Ltd., Business Overview
  • Table 70: Torrent Pharmaceuticals Ltd., Financial Overview